These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 1555133)

  • 1. Clinical trials: where do we go from here?
    Cruess AF; Ballantyne M
    Can J Ophthalmol; 1992 Feb; 27(1):3-5. PubMed ID: 1555133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal and maximin sample sizes for multicentre cost-effectiveness trials.
    Manju MA; Candel MJ; Berger MP
    Stat Methods Med Res; 2015 Oct; 24(5):513-39. PubMed ID: 25656551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reliability, effect size, and responsiveness of health status measures in the design of randomized and cluster-randomized trials.
    Diehr P; Chen L; Patrick D; Feng Z; Yasui Y
    Contemp Clin Trials; 2005 Feb; 26(1):45-58. PubMed ID: 15837452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of information analyses of economic randomized controlled trials: the treatment of intermittent claudication.
    Groot Koerkamp B; Spronk S; Stijnen T; Hunink MG
    Value Health; 2010; 13(2):242-50. PubMed ID: 19818058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test.
    Brookes ST; Whitely E; Egger M; Smith GD; Mulheran PA; Peters TJ
    J Clin Epidemiol; 2004 Mar; 57(3):229-36. PubMed ID: 15066682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incremental net benefit in randomized clinical trials.
    Willan AR; Lin DY
    Stat Med; 2001 Jun; 20(11):1563-74. PubMed ID: 11391688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accounting for between-study variation in incremental net benefit in value of information methodology.
    Willan AR; Eckermann S
    Health Econ; 2012 Oct; 21(10):1183-95. PubMed ID: 21882285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Demographic analysis of randomized controlled trials in bladder cancer.
    Bachir BG; Shariat SF; Zlotta A; Svatek R; Black PC; Shah JB; Kassouf W; ;
    BJU Int; 2013 Mar; 111(3):419-26. PubMed ID: 22928764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Power and money in cluster randomized trials: when is it worth measuring a covariate?
    Moerbeek M
    Stat Med; 2006 Aug; 25(15):2607-17. PubMed ID: 16217840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
    Sharma MR; Maitland ML; Ratain MJ
    Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spinal cord stimulation versus reoperation for failed back surgery syndrome: a cost effectiveness and cost utility analysis based on a randomized, controlled trial.
    Wilkinson HA
    Neurosurgery; 2008 Aug; 63(2):E376; author reply E376. PubMed ID: 18797322
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficient design of cluster randomized and multicentre trials with unknown intraclass correlation.
    van Breukelen GJ; Candel MJ
    Stat Methods Med Res; 2015 Oct; 24(5):540-56. PubMed ID: 21937473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Designing a sequentially randomized study with adherence enhancing interventions for diabetes patients.
    Buyze J; Van Rompaye B; Goetghebeur E
    Stat Med; 2010 May; 29(10):1114-26. PubMed ID: 20101597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
    Chen MH; Willan AR
    Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of information methods for planning and analyzing clinical studies optimize decision making and research planning.
    Willan AR; Goeree R; Boutis K
    J Clin Epidemiol; 2012 Aug; 65(8):870-6. PubMed ID: 22609138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, analysis and presentation of factorial randomised controlled trials.
    Montgomery AA; Peters TJ; Little P
    BMC Med Res Methodol; 2003 Nov; 3():26. PubMed ID: 14633287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global randomized trials: the promise of India and China.
    Perkovic V; Patil V; Wei L; Lv J; Petersen M; Patel A
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():92-6. PubMed ID: 22810456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The expanded role of randomized clinical trials.
    Kupfer C
    Am J Ophthalmol; 1996 Dec; 122(6):883-5. PubMed ID: 8956644
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.